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Abstract
Background: Both thermotherapy and arsenic have been shown to be active against a broad
spectrum of cancers. To reduce the limitations of conventional thermotherapy, improve
therapeutic anticancer activity, reduce the toxicity of arsenic on normal tissue, and increase tissue-
specific delivery, we prepared a nanosized As2O3/Fe3O4 complex (Fe3O4 magnetic nanoparticles
encapsulated in As2O3). We assessed the thermodynamic characteristics of this complex and
validated the hyperthermia effect, when combined with magnetic fluid hyperthermia (MFH), on
xenograft HeLa cells (human cervical cancer cell line) in nude mice. We also measured the effect
on the expression of CD44v6, VEGF-C, and MMP-9 which were related to cancer and/or metastasis.
Results:  The nanosized As2O3/Fe3O4  particles were approximately spherical, had good
dispersibility as evidenced by TEM, and an average diameter of about 50 nm. With different
concentrations of the nanosized As2O3/Fe3O4 complex, the correspondingsuspension of magnetic
particles could attain a steady temperature ranging from 42°C to 65°C when placed in AMF for 40
min. Thermochemotherapy with the nanosized As2O3/Fe3O4  complex showed a significant
inhibitory effect on the mass (88.21%) and volume (91.57%) of xenograft cervical tumors (p < 0.05
for each measurement, compared with control). In addition, thermochemotherapy with the
nanosized As2O3/Fe3O4 complex significantly inhibited the expression of CD44v6, VEGF-C, and
MMP-9 mRNA (p < 0.05 for each).
Conclusion: As2O3/Fe3O4 complex combined with MFH had is a promising technique for the
minimally invasive elimination of solid tumors and may be have anticancerometastasic effect by
inhibiting the expression of CD44v6, VEGF-C, and MMP-9.
Background
Clinically, heating of certain organs or tissues to tempera-
tures between 41°C-46°C (the procedure is termed tissue
"hyperthermia") has been effective in tumor therapy.
Presently, traditional thermotherapy protocols utilize
radiofrequency waves, microwaves, or lasers, each of
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which has many limitations. With the development of
nanotechnology, magnetic nanoparticles have been used
not only as drug carriers but also in tumor hyperthermia,
as such particles absorb energy from high frequency AMF.
Nanoscaled magnetic fluid has been found to absorb
much more energy than conventional materials, and this
energy is further transferred to tumor cells resulting in
tumor temperatures of 42°C-45°C. This process, termed
"Magnetic Fluid Hyperthermia (MFH)" can be used for
the treatment of either non-cancer diseases or tumors [1].
Magnetic nanoparticles may be good thermoseeds for
localized hyperthermia treatment of cancers [2], permit-
ting the heating of and damage to normal tissue to be
avoided, thus overcoming the limitations of conventional
heat treatment. Fe2O3  magnetic nanoparticles used in
MFH were reported to have a significant therapeutic effect
on xenograft liver cancer in nude mice [3]. Depending on
the applied temperature and the duration of heating this
treatment either results in direct tumor cell killing or
makes the cells more susceptible to concomitant radio- or
chemotherapy. Numerous groups are working in this field
worldwide, but only one approach has been tested in clin-
ical trials so far.
Metastatic spread of the solid tumor depends on a critical
cascade of events, which includes tumor cell adhesion to
a distant site, extracellular matrix degradation, migration,
proliferation, and ultimately neovascularization. Tumors
that produce higher levels of metastasis-related factors,
such as proteins encoded by the "cluster of differentiation
44v6" (CD44v6) gene, and the genes encoding vascular
endothelial growth factor-C (VEGF-C) and matrix metal-
loproteinase-9 (MMP-9), may show more aggressive
behavior than do tumors negative for these factors. Thus,
a treatment that could inhibit the expression of these
tumor metastasis-related factors would be of great inter-
est.
Arsenic is a well-documented carcinogen that also appears
to be a valuable therapeutic tool in cancer treatment [4].
The first use of As2O3 in cancer therapy was to treat acute
promyelocytic leukemia (APL) [5]. The results of in vitro
research and clinical trials have shown that As2O3 is effec-
tive in inhibiting tumor growth, and in inducing the dif-
ferentiation and apoptosis of APL cells. Because of its
significant anti-cancer effects, As2O3 has been tested in
patients with other tumor types, including gastric cancer
[6], neuroblastoma [7], esophageal carcinoma [8], and
head and neck cancers [9]. Moreover, As2O3 was shown to
inhibit tumor metastasis by reducing the expression of
metastasis-related genes [10-12].
The purpose of this study was to prepare nanosized
As2O3/Fe3O4  complex for tumor thermochemotherapy
and validate its effect on xenograft tumor in nude mice as
a premature treatment. We also tested the ability of a
nanosized As2O3/Fe3O4 complex combined with MFH to
inhibit the expression of metastasis-associated genes.
Methods
Reagents
As2O3 was purchased from Sigma (St Louis, MO; Lot
A1010). A 1 mM stock solution in RMPI 1640 medium
(Gibco) was prepared, stored at 0-4°C, and diluted before
use. Calf serum from newborn animals was obtained from
Si-Ji-Qing Biotechnology Co. (Hangzhou, China). HEPES
(the free acid) and trypsin were obtained from Amresco
Corp. RNAiso reagent, AMV retroviridase, dNTPs,
Oligo(dT)18,  Taq  DNA polymerase, and DNA markers
were purchased from Takara Biotechnology Co. (Dalian,
China).  VEGF-C,  CD44v6, and MMP-9  primers were
obtained from Shen-neng-bo-cai Biotechnology (Shang-
hai, China).
Preparation of the Nanosized As2O3/Fe3O4 Complex
Fe3O4 magnetic nanoparticles were prepared by chemical
coprecipitation. Briefly, solutions of FeCl3·6H2O and
FeCl2·4H2O were mixed, at a molar ratio of iron (II) to
iron (III) of about 0.6, under nitrogen purging and with
stirring, with ammonia (1.5 mol/L) added dropwise until
the pH attained pH 9. A dark precipitate (Fe3O4 magnetic
nanoparticles) appeared rapidly, and stirring was contin-
ued for 30 min. After 30 min at 90°C, the Fe3O4 magnetic
nanoparticles were isolated using a permanent magnet
and dried in vacuo.
The nanosized As2O3/Fe3O4 complex was prepared by an
impregnation process. Briefly, Fe3O4 magnetic nanoparti-
cles were added to a solution of As2O3 (0.01 mg/mL, pH
= 5, adjusted with acetic acid) with sonication. After 30
min of thermal treatment at 80°C, the resulting nano-
sized As2O3/Fe3O4 complex was centrifuged at 2,000 g/
min for 10 min, rinsed twice with absolute ethanol, and
dried under vacuo. The diameter of the nanosized As2O3/
Fe3O4 complex particles was measured by transmission
electron microscopy (TEM; Hitachi H-600 instrument;
Japan).
Heat Testing of Nanosized As2O3/Fe3O4 Complex in Vitro
The nanosized As2O3/Fe3O4 complex was dispersed in
0.9% (w/v) NaCl, at Fe3O4 concentrations of 0.5, 1.0,
1.5, 2.0 and 2.5 mg/mL, and 2 mL aliquots of magnetic
fluids were added to flat-bottomed cuvettes and placed in
a high frequency electromagnetic field. The distance from
the bottom of the cuvette to the center of the source
(coils) of the high frequency field was 5 mm. The output
frequency was 230 kHz and the output current 20 A.
Throughout 1 h of incubation, the temperature was meas-
ured every 5 min.BMC Biotechnology 2009, 9:84 http://www.biomedcentral.com/1472-6750/9/84
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Cell Culture
HeLa cells (a human cervical cancer cell line, provided by
the Institute of Biochemistry and Cell Biology, Shanghai
Institute of Biological Sciences, Chinese Academy of Sci-
ences) were maintained in RPMI-1640 medium supple-
mented with 10% (v/v) heat-inactivated fetal calf serum,
100 units/mL penicillin, and 100 mg/L streptomycin, at
37°C in a 5% CO2/95% air (v/v) incubator under 95%
relative humidity.
Animal Experiments
Female BALB/C nude mice, aged 6 weeks, were purchased
from the Lakes Animal Experimental Center of the Insti-
tute of Biochemistry and Cell Biology, Shanghai Institute
of Biological Sciences, China. The animal experiments
were approved by the regional animal ethics committee
and the mice treated in accordance with the international
animal ethics guidelines. All of the mice were maintained
in the animal facility of School of Basic Medical Sciences,
Southeast University, China. Mice were housed up to 8
animals per cage in individual ventilation cages and fed
with specific pathogen-free mice chow ad libitum. Expo-
nentially growing HeLa cells (density >105 cells/mL) were
injected subcutaneously around the right posterior limb
rump. When tumor diameters reached 0.5 cm, mice were
divided into four groups of eight mice each: (1) sterile
0.9% (w/v) NaCl (control group), (2) 5 μM As2O3 dis-
persed in 0.9% (w/v) NaCl (As2O3 group), (3) 1 mg/mL of
Fe3O4 dispersed in 0.9% (w/v) NaCl (Fe3O4 group), and
(4) 1 mg/mL of Fe3O4 and 5 μM As2O3 dispersed in 0.9%
(w/v) NaCl (As2O3/Fe3O4 group). The solution/suspen-
sion (1, 2, 3, or 4) were directly injected into tumors with
a volume equal to half the tumor volume. In our study, we
applied the method of multipoint injection, following
clockwise, at the 3, 6, 9, and 12 o'clock points. The tumors
of the Fe3O4 and As2O3/Fe3O4 groups were exposed to
high frequency AMF (f = 230 kHz, I = 20 A) for 30 min,
three times at 24 h intervals [13]. Tumor temperature was
measured at multipoint using an infrared thermometer
(ZyTemp-TN18 model; China). Mice were sacrificed after
6 weeks, and the mass and volume of each tumor were
measured. Tumor growth inhibition was evaluated by
measuring mass and volume inhibition proportions.
Mass inhibition (IM) was calculated as (1 - Relative tumor
mass) × 100%, where relative tumor mass (RTM) was the
mean tumor mass of the experimental group divided by
the mean tumor mass of the control group. Similarly, vol-
ume inhibition (IV) was calculated as (1 - Relative tumor
volume) × 100%, where relative tumor volume (RTV) was
the mean tumor volume of the experimental group
divided by the mean tumor volume of the control group.
Expression of CD44V6, VEGF-C, and MMP-9 after 
Thermochemotherapy of HeLa cells
In vitro treatment and sampling
HeLa cells were seeded in 50 mL culture flasks at 6 × 105
cells per flask. After 24 hours, cells were grown in: (1)
RPMI1640 medium containing 10% (v/v) fetal calf serum
(positive control group); (2) 5 μM or 10 μM As2O3 (As2O3
groups); (3) 1 mg/mL of Fe3O4 magnetic nanoparticles
with or without AMF exposure (Fe3O4 groups); or (4) 1
mg/mL of Fe3O4 and 5 μM or 10 μM As2O3 with AMF
exposure (As2O3/Fe3O4 complex groups), with six flasks
used to test each of the above conditions. AMF exposure
consisted of electromagnetic exposure for 60 min under
high frequency AMF (f = 230 kHz, I = 20 A). All flasks were
incubated for 48 hours and cells were thereafter isolated.
RNA isolation
RNA was extracted from cells using the RNAiso reagent,
according to the supplier's protocol. The purity and con-
centration of RNA were determined by spectrophotome-
try at 260 nm. The quality of RNA was checked by
electrophoresis of 2-3 μL samples in 1% (w/v) agarose
gels, staining with ethidium bromide, and examining the
28S and 18S rRNA bands under UV light. No significant
degradation was observed in any RNA sample.
Semi-quantitative reverse transcription polymerase chainreaction 
(RT-PCR)
Total RNA was denaturated for 10 min at 70°C. Each RT
reaction (20 μL volume) contained 2 μL of total RNA,1 μL
of Oligo dT18, 2 μL of each dNTP (10 mM), 0.5 μL RNa-
sin, 1 μL AMV retroviridase, 4 μL 5 × AMV buffer, and 9.5
μL of DEPC water. Each reaction mixture was incubated
for 1 hour at 42°C, and the reverse transcriptase was inac-
tivated by heating at 95°C for 5 min. Each cDNA product
was frozen at -20°C until use.
PCR reactions were performed in 25 μL volumes contain-
ing 5 μL cDNA, 2 μL 10× PCR buffer, 2 μL dNTP (2.5
mM), 1 μL sense primers, and 1 μL antisense primers [14-
16] (20 pmol/μL, please see Table 1; β-actin primers were
used as an internal control), 0.5 μL Taq DNA polymerase
(5 U/μL), 2.5 μL MgCl2 (25 mM), and 11 μL DEPC water.
After initial denaturation at 96°C for 3 min, the mixtures
were subjected to a varying number of denaturation cycles
(each at 1 min at 94°C), annealing (1 min at 56°C for β-
actin; 57°C for VEGF-C; and 60°C for other genes) and
extension (2 min at 72°C), and a final extension at 72°C
for 10 min, in a PTC-100 thermal cycler (MJ Research,
Watertown, MA). Samples were stored at -20°C. For each
reaction, a negative control employed distilled water
instead of cDNA, and cDNA from untreated HeLa cells
served as the positive control.BMC Biotechnology 2009, 9:84 http://www.biomedcentral.com/1472-6750/9/84
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Table 1: PCR primers and PCR conditions.
Gene Primers Tm (°C) No. of cycles Product size (bp) Reference
CD44v6 5'-GACACATATTGCTTCAATGCTTCAGC-3' 60 35 348 [14]
5'-TACTAGGAGTTGCCTGGATGGTAG-3'
VEGF-C 5'-AGACTCAATGCATGCCACG-3' 57 35 435 [15]
5'-TTGAGTCATCTCCAGCATCC-3'
MMP-9 5'-GTGCTGGGCTGCTGCTTTGCTG-3' 60 35 303 [15]
5'-GTCGCCCTCAAAGGTTTGGAAT-3'
β-actin 5'-CGTCTGGACCTGGCTGGCCGGGACC-3' 56 28 600 [16]
5'-CATGAAGCATTTGCGGTGGACGATG-3'
TEM image of the nanosized As2O3/Fe3O4 complexes Figure 1
TEM image of the nanosized As2O3/Fe3O4 complexes.
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Amplified PCR products were electrophoresed with DNA
markers, on 2% (w/v) agarose gels containing ethidium
bromide. Bands were visualized under UV light and each
gel image was captured by a digital camera. Imagetool 2.0
software was used for semi-quantitative analysis of elec-
trophoresis results.
Results
Characteristics of the Nanosized As2O3/Fe3O4 Complex
The nanosized As2O3/Fe3O4  complex particles were
approximately spherical, uniform in size, and had good
dispersibility, with an average diameter by TEM of about
50 nm (Figure 1) [17]. Upon dispersion in 0.9% (w/v)
NaCl and exposure to high frequency AMF (output fre-
quency 230 kHz, output current 20 A) for 60 min, the
nanosized As2O3/Fe3O4 complexes increased the tempera-
ture of magnetic fluid (MF) from 42°C to 65°C, depend-
ing on the concentration of Fe3O4  (Figure 2), with a
permanent change seen after 40 min of electromagnetic
exposure. As a 1 mg/mL concentration of Fe3O4 in the
As2O3/Fe3O4 complex increased the MF temperature to
47°C, we chose this Fe3O4 concentration for further exper-
iments.
In Vivo Inhibitory Effects of the As2O3/Fe3O4 Complex and 
AMF exposure on Xenograft Cervical Cancer in Nude Mice
Following intratumor injection of simple Fe3O4 magnetic
nanoparticles or nanosized As2O3/Fe3O4 complexes, and
exposure to high frequency AMF (f = 230 kHz, I = 20 A)
for 30 min, almost the entire tumor got heated by the nan-
oparticles and the temperature of tumors rose to 44°C-
45°C. Compared with control tumors, the tumors of all
experimental groups were smaller (Figure 3 &4). The mass
and volume inhibition rates in the As2O3/Fe3O4 group
were 88.21% and 91.57%, respectively, significantly
higher than observed in the control, the As2O3, and the
Fe3O4 groups (p < 0.05 for each, Table 2). Histological
examination revealed that, in both the As2O3/Fe3O4 and
Fe3O4 groups, many black nanoparticles accumulated in
the stroma of the tumors, with widespread tumour necro-
sis surrounding the nanoparticles. The necrotic areas of
the As2O3 group were larger than those of the control
group (Figure 5).
Presently, clinical thermotherapy induces substantial
damage to surrounding healthy tissues. We applied a
multipoint injection strategy, injecting nanoparticles into
the 3, 6, 9, and 12 o'clock points of each tumor, to ensure
Heating test curve of nanosized As2O3/Fe3O4 complex fluid in AMF in vitro Figure 2
Heating test curve of nanosized As2O3/Fe3O4 complex fluid in AMF in vitro. Output frequency = 230 kHz, output 
current = 20A; the concentrations of Fe3O4 were 0.5, 1.0, 1.5, 2.0, and 2.5 mg/mL.
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almost whole tumor to get homogeneously heated and
minimize damage to surrounding tissue. Thus, because of
the targeted and localized thermogenic activity of MFH,
normal tissue without magnetic particles should not be
damaged. We found that, because of the dual activity
(chemotherapy and hyperthermia) of the nanoparticles,
the therapeutic effect of Fe3O4  magnetic nano-micro-
spheres containing As2O3, in combination with AMF
exposure, was greater than that of Fe3O4 magnetic nano-
particles combined with AMF exposure, and that of As2O3
treatment alone.
Semi-quantitative RT-PCR
HeLa cells exposed to free As2O3 or to nanosized As2O3/
Fe3O4  complexes under AMF showed dose-dependent
inhibition of CD44v6, VEGF-C, and MMP-9 mRNA syn-
thesis, which indicated that As2O3 can inhibit CD44v6,
VEGF-C and MMP-9 mRNA expression. In contrast, expo-
sure to Fe3O4 magnetic nanoparticles and AMF inhibited
expression of VEGF-C, but not of CD44v6 and MMP-9
(Figure 6, Table 3).
Discussion
Heat therapies such as hyperthermia and thermoablation
are very promising approaches in the treatment of cancer.
Compared with available hyperthermia modalities, MFH
yields better results in uniform heating of the deeply situ-
ated tumors. In this approach, fluid consisting of super-
paramagnetic nanoparticles (magnetic fluid) is delivered
to the tumor. An AMF is then used to heat the particles
and the corresponding tumor, thereby ablating it[18].
Interstitial hyperthermia following direct injection of
nanoparticles has also been proven successful in many
animal models. Jordan A et al. reported good effects of
MFH on C3H mammary carcinoma in vivo[19]. A variety
of magnetic fluids have been applied using related tech-
niques (differing mostly in the formulation of the nano-
particles), but so far only few of these approaches has
been successfully translated from research to clinical
stage.
All magnetic nanoparticles used so far in vivo are com-
posed of the iron oxides magnetite (Fe3O4) and
maghemite (γ-Fe2O3) due to their low toxicity and their
known pathways of metabolism. As demonstrated by X-
ray diffraction, Fe3O4 nanoparticles are of the spinel type
and magnetic Fe3O4 [17,20] can absorb a considerable
amount of energy and transform this energy into heat
when exposed to AMF. We successfully prepared nano-
sized As2O3/Fe3O4 complexes using co-precipitation and
impregnation processes. These particles were successful in
the warming of tumors upon exposure to high frequency
AMF, suggesting their usefulness in hyperthermia proto-
cols. By adjusting the concentration of Fe3O4, we could
select a suitable temperature (42°C-46°C) for tumor
hyperthermia. At a 1 mg/mL Fe3O4 concentration in the
As2O3/Fe3O4 complex, the temperature of the magnetic
fluid rose to 47°C after exposure to high frequency AMF
for 30 min.
Nanosized As2O3/Fe3O4 complexes, combined with MFH,
had a significant therapeutic effect on xenograft tumor in
nude mice, by inducing tumor cell apoptosis and inhibit-
ing cell growth. We injected complexes directly into the
tumor tissue, rather than into healthy tissue at the tumor
boundary, thus delivering nanoparticles to the desired
regions. Such nanoparticles may be internalized into
tumor cells and organelles [19], and transmission electron
microscopy showed that the nanosized As2O3/Fe3O4 com-
plex particles were indeed so internalized, both into cells
and into organelles such as the nucleoli and lysosomes
[13]. Although the mechanism by which nanoparticles
enter tumor cells is not yet known, pinocytosis or penetra-
tion may be in play, as the nanoparticle diameter is small.
Moreover, hyperthermia may increase the permeability of
biological membranes. These findings suggest that the
As2O3/Fe3O4 composite nanoparticles may be useful as
thermoseeds for localized hyperthermia treatment of can-
cers, without damaging normal tissue, thus overcoming
the limitations of conventional heat treatment. Moreover,
by using these complexes, As2O3 can be localized to tumor
tissue, thus reducing the As2O3 toxicity to normal tissue.
This method may therefore allow a combination of local-
ized thermogenic and chemotherapeutic activity, even in
tumors located deep inside the body, simultaneously
minimizing damage caused by heat and toxicity to normal
tissue surrounding the tumor. The MFH also can act as a
temperature control switch in vivo by controlling the con-
Table 2: Extent of volume and mass inhibition of xenograft cervical cancer in nude mice after treatment.
Group Tumor volume (mm3)
(  ± S, n = 8)
Tumor mass (g)
(  ± S, n = 8)
Volume inhibition (%) Mass inhibition (%)
Control group 931.51 ± 284.26 0.789 ± 0.143 0 0
Single As2O3 group 616.94 ± 147.96(1) 0.634 ± 0.056(1) 33.77 19.65
Single Fe3O4 magnetic nanoparticles group 132.79 ± 36.30(1) 0.128 ± 0.029(1) 85.74 83.78
Nanosized As2O3/Fe3O4 complex group 78.50 ± 32.73(1) 0.093 ± 0.028(1) 91.57 88.21
(1) p < 0.05 vs. control group. These measurements were obtained 6 weeks after the start of treatment.
X XBMC Biotechnology 2009, 9:84 http://www.biomedcentral.com/1472-6750/9/84
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centration of Fe3O4, thus minimizing the risk of overheat-
ing during therapy. In comparison with traditional
hyperthermia, the double function (chemotherapy and
hyperthermia) and targeted activity of the combination of
nanosized As2O3/Fe3O4 complexes and MFH are most
important characteristics. Based on the data in Table 2 and
Figure 4, although the tumor inhibition appears to be pri-
marily due to the heat, we can still see that the combina-
tion was more effective than either Fe3O4  magnetic
nanoparticles plus MFH, or As2O3 treatment alone. In
addition, the heat created during thermotherapy may
directly damage tumor cells or may make cells more sus-
ceptible to accompanying chemotherapy [21].
MFH has been undergoing clinical testing. In three clinical
studies the safety and the feasibility of the technique has
been proven. In March 2003, the first clinical feasibility
study on magnetic nanoparticle hyperthermia was started
with 14 patients suffering from glioblastoma multiforme
[22]. All patients received a neuro-navigationally guided
injection of the magnetic fluid into the tumor. The
amount of fluid and the spatial distribution of the depots
were planned in advance by means of a specially devel-
oped treatment planning software following magnetic res-
onance imaging (MRI). The actually achieved magnetic
fluid distribution was measured by computed tomogra-
phy (CT).
In prostate cancer, a direct injection technique of MFH
was investigated in phase-I-study. The feasibility and good
tolerability was shown in the trial[23,24]. This novel
approach requires specific tools for planning, quality con-
trol and thermal monitoring, based on appropriate imag-
ing and modelling techniques. Treatment planning was
carried out using CT of the prostate. Nanoparticle suspen-
sions were injected transperineally into the prostate under
transrectal ultrasound and flouroscopy guidance.
Another prospective feasibility study enrolled 22 patients
with proven recurrences and residual tumors (non-resect-
able and pre-treated, e.g. prostate and cervix carcinoma,
soft tissue sarcoma)[25]. Three implantation methods
were established: Infiltration under CT fluoroscopy
(group A), TRUS (transrectal ultrasound)--guided implan-
tation with X-fluoroscopy (group B) and intra-operative
infiltration under visual control (group C). In group A and
B the distribution of the nanoparticles can be planned
prior to implantation on the basis of three-dimensional
image datasets. These approaches of MFH above were well
tolerated by patients.
MFH is suitable for treatment of superficial tumors by
direct injection of nanoparticle suspension, which was
first reported in 1997 [19]. For deep tumors, the feasibility
and good tolerability of different injection techniques
(CT, ultrasound or X-fluoroscopy guided) were shown.
Endoscope such as Oesophagoscope and vaginoscope can
be respectively used as guiding devices for esophageal can-
cer and cervical cancer. A different approach of using mag-
netic nanoparticles for heating tumor cells is termed
ferromagnetic embolization hyperthermia. This tech-
nique, which uses a feeding artery to carry nanoparticles
into the tumor, seems to be especially well suited for the
treatment of hepatic malignancies due to the differences
in blood supply between hepatic tumor cells and normal
liver parenchyma. Several preclinical studies on arterial
embolization hyperthermia of liver cancer were reported
[26-28], and Granov reported this treatment on clinical
use[29].
Metastasis, a unique characteristic of malignant tumors, is
the most difficult issue in the clinical treatment of cancer
and the major cause of death. Hyperthermia may trigger
immune responses that inhibit the metastasis of graft
tumors [30].
"Cluster of differentiation 44" (CD44) is a cell surface
adhesion molecule that recognizes hyaluronate and medi-
ates diverse functions, such as cell-cell and cell-matrix
adhesion, lymphocyte homing, and T-cell adhesion and
activation. CD44 exists as a standard form (CD44s) and as
multiple isoforms, each generated by alternative splicing
of up to 10 variant exons encoding parts of the extracellu-
lar domain. CD44, especially the CD44v6 variant, has a
role in tumor progression and metastasis in human can-
cers [31]. Expression of CD44v6 has been found to corre-
Morphological changes of xenograft tumors in nude mice  treated by different methods Figure 3
Morphological changes of xenograft tumors in nude 
mice treated by different methods. a. control group 
(sterile 0.9% [w/v] NaCl); b. As2O3 group (5 μM As2O3 dis-
persed in 0.9% [w/v] NaCl); c. Fe3O4 group (1 mg/mL of 
Fe3O4 magnetic nanoparticles dispersed in 0.9% [w/v] NaCl 
plus MFH); d. As2O3/Fe3O4 group (1 mg/mL of Fe3O4 and 5 
μM As2O3 dispersed in 0.9% [w/v] NaCl plus MFH). The 
tumors become smaller in animals treated with protocols 'a' 
to 'd'. Compared with the control, each group showed signif-
icant reductions in tumor volume and mass (p < 0.05 for 
both).BMC Biotechnology 2009, 9:84 http://www.biomedcentral.com/1472-6750/9/84
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late significantly with lymphatic and/or hematogenous
metastasis. Following the administration of As2O3  to
SGC9701 cells, expression of CD44 decreased, suggesting
that As2O3 inhibited CD44 expression [32].
In the vascular endothelial growth factor (VEGF) family,
VEGF-C is a ligand for VEGF receptor (VEGFR)-3, a tyro-
sine kinase receptor that is predominantly expressed in
the endothelium of lymphatic vessels. VEGF-C plays an
important role in tumor metastasis by mediating the for-
mation of lymphatic vessels. Most cancer cells express
VEGF-C, and such expression positively correlates with
tumor angiogenesis and metastasis [33]. As2O3 has been
reported to inhibit VEGF expression, preventing the pro-
liferation, invasion, and metastasis of solid tumors [34].
In addition, expression of VEGF mRNA and protein by
fibrosarcomas was significantly inhibited after thermo-
therapy at 42°C [35]. Moreover, the density of tumor ves-
sels in gliomas was reduced after thermotherapy and even
more after thermochemotherapy, indicating that thermo-
Part (A): Relative tumor mass (RTM) of xenograft cervical cancer in nude mice after treatment Figure 4
Part (A): Relative tumor mass (RTM) of xenograft cervical cancer in nude mice after treatment. Part (B): Rel-
ative tumor volume (RTV) of xenograft cervical cancer in nude mice after treatment. These measurements were 
obtained 6 weeks after the start of treatment.
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Histological changes in xenograft tumors (H & E) (×200) Figure 5
Histological changes in xenograft tumors (H & E) (×200). Sections from the (A) control, (B) As2O3, (C) Fe3O4, and (D) 
As2O3/Fe3O4 groups are shown (T, tumor tissue; N, necrosis; M, materials of Fe3O4 or As2O3/Fe3O4. Histological examination 
revealed that the necrotic areas in B, C, and D were much larger than the intrinsic necrosis of the tumor shown in A.
   
   
Table 3: Results of semi-quantitative RT-PCR analysis
relative gray value (gene/β-actin), (  ± S)
G e n e P 1 2345 6
CD44v6 0.386 ± 0.049 0.396 ± 0.052 0.438 ± 0.115 0.210 ± 0.075(1) 0.244 ± 0.120(1) 0.142 ± 0.064(1)(2) 0.117 ± 0.030(1)(3)
VEGF-C 0.605 ± 0.166 0.514 ± 0.083 0.398 ± 0.079(1) 0.305 ± 0.132(1)(2) 0.344 ± 0.038(1) 0.095 ± 0.016(1)(3) 0.150 ± 0.036(1)
MMP-9 0.966 ± 0.205 1.053 ± 0.222 0.997 ± 0.093 0.461 ± 0.170(1) 0.466 ± 0.121(1) 0.244 ± 0.107(1)(2) 0.220 ± 0.098(1)(3)
CD44v6: (1) p < 0.05 vs. P, (2) p < 0.05 vs. 3, (3) p < 0.05 vs. 4; VEGF-C: (1) p < 0.05 vs. P, (2) p < 0.05 vs. 2 and 4, (3) p < 0.05 vs. 6; MMP-9: (1) p < 
0.05 vs. P, (2) p < 0.05 vs. 3, (3) p < 0.05 vs. 4.
P, positive control (untreated HeLa cells); 1, Fe3O4 without MFH; 2, Fe3O4 plus MFH; 3, nanosized As2O3 (5 μM)/Fe3O4 plus MFH; 4, 5 μM As2O3; 
5, nanosized As2O3 (10 μM)/Fe3O4 plus MFH group; 6, 10 μM As2O3.
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Expression of (A) CD44v6, (B) VEGF-C, and (C) MMP-9 mRNA after treatment of HeLa cells Figure 6
Expression of (A) CD44v6, (B) VEGF-C, and (C) MMP-9 mRNA after treatment of HeLa cells. Lanes: P, positive 
control (untreated HeLa cells); 1, Fe3O4 without MFH; 2, Fe3O4 plus MFH; 3, nanosized As2O3 (5 μM)/Fe3O4 plus MFH; 4, 5 
μM As2O3; 5, nanosized As2O3 (10 μM)/Fe3O4 plus MFH; 6, 10 μM As2O3;N, negative control; M, DNA marker.
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therapy may inhibit the expression of VEGF mRNA and
protein [36].
Matrix metalloproteinases (MMPs) are a family of zinc-
and calcium-dependent enzymes that degrade extracellu-
lar matrix proteins, such as laminin, fibronectin, and col-
lagen.  MMPs  mediate the invasive properties of most
malignant cells and promote angiogenesis through their
ability to degrade basement membranes and to remodel
extracellular matrix architecture. In particular, MMP-9
specifically degrades collagen IV, the major component of
the basement membrane. Expression of MMP-9 has been
found to correlate with tumor invasiveness and metasta-
sis, including lymph node metastasis[37]. As2O3 reduced
the expression of MMP-9 by nasopharyngeal carcinoma
cells in vitro, and decreased their invasive and metastatic
properties [12]. Using As2O3/Fe3O4  nanoparticles, we
found that As2O3 dose-dependently inhibited the expres-
sion of CD44v6, VEGF-C, and MMP-9 mRNA. Moreover,
thermotherapy alone inhibited the expression of VEGF-C
mRNA to some extent.
Conclusion
The nanosized As2O3/Fe3O4  complexes described here
possess not only the chemotherapeutic activity of As2O3
but also the characteristic of strong magnetic responsive-
ness arising from the presence of Fe3O4. These particles are
suitable for treating superficial tumors by direct injection
and for deep tumors by using different injection tech-
niques (CT, ultrasound or X-fluoroscopy guided, intraop-
eratively under visual control), because they absorb
energy from high frequency AMF and also have chemo-
therapeutic effects. For early stage tumors, thermochemo-
therapy of nanosized As2O3/Fe3O4 complexes could be
used as preoperative treatment because of reducing tumor
volume and intraoperative bleeding, creating better con-
ditions for latter surgery. In addition, it may be can inhibit
tumor metastasis to some extent.
Most researches of MFH in this field applied so far have
only been evaluated in preclinical studies. In spite of some
Phase I trials have been carried out, it is still too early to
claim therapeutic advantages for the applied method
because survival benefit or time to progression were not
defined endpoints of the finished feasibility studies. How-
ever, the ongoing Phase II trials will provide an initial
indication whether MFH can improve survival and/or
quality of life.
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